ID   PES 43
AC   CVCL_VP92
SY   PES-43; PES43; PE-MEL-43; PE-Mel-43
DR   cancercelllines; CVCL_VP92
DR   Wikidata; Q98128548
RX   PubMed=10837406;
RX   PubMed=12488552;
RX   PubMed=16638848;
RX   PubMed=21424129;
RX   PubMed=21863025;
RX   PubMed=29492214;
CC   Sequence variation: Mutation; HGNC; HGNC:1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=29492214).
CC   Sequence variation: Mutation; HGNC; HGNC:1787; CDKN2A; Simple; p.Trp110Ter (c.330G>A) (p.Gly125Arg, c.373G>A); ClinVar=VCV000376303; Zygosity=Unspecified (PubMed=29492214).
CC   Derived from site: Metastatic; Lung; UBERON=UBERON_0002048.
DI   NCIt; C3224; Melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_VP91 ! PES 41
OI   CVCL_VP93 ! PES 47
SX   Sex unspecified
AG   Age unspecified
CA   Cancer cell line
DT   Created: 07-09-18; Last updated: 19-12-24; Version: 10
//
RX   PubMed=10837406; DOI=10.1093/intimm/12.6.787;
RA   Pirozzi G., Lombari V., Zanzi D., Ionna F., Lombardi M.L., Errico S.,
RA   Ruggiero G., Manzo C.;
RT   "CD40 expressed on human melanoma cells mediates T cell co-stimulation
RT   and tumor cell growth.";
RL   Int. Immunol. 12:787-795(2000).
//
RX   PubMed=12488552; DOI=10.1124/mol.63.1.192;
RA   Tentori L., Portarena I., Barbarino M., Balduzzi A., Levati L.,
RA   Vergati M., Biroccio A., Gold B., Lombardi M.L., Graziani G.;
RT   "Inhibition of telomerase increases resistance of melanoma cells to
RT   temozolomide, but not to temozolomide combined with poly (adp-ribose)
RT   polymerase inhibitor.";
RL   Mol. Pharmacol. 63:192-202(2003).
//
RX   PubMed=16638848; DOI=10.1158/1078-0432.CCR-05-1940;
RA   Scala S., Giuliano P., Ascierto P.A., Ierano C., Franco R.,
RA   Napolitano M., Ottaiano A., Lombardi M.L., Luongo M., Simeone E.,
RA   Castiglia D., Mauro F., De Michele I., Calemma R., Botti G.,
RA   Caraco C., Nicoletti G., Satriano R.A., Castello G.;
RT   "Human melanoma metastases express functional CXCR4.";
RL   Clin. Cancer Res. 12:2427-2433(2006).
//
RX   PubMed=21424129; DOI=10.3892/or.2011.1220;
RA   Manca A., Sini M.C., Izzo F., Ascierto P.A., Tatangelo F., Botti G.,
RA   Gentilcore G., Capone M., Mozzillo N., Rozzo C., Cossu A., Tanda F.,
RA   Palmieri G.;
RT   "Induction of arginosuccinate synthetase (ASS) expression affects the
RT   antiproliferative activity of arginine deiminase (ADI) in melanoma
RT   cells.";
RL   Oncol. Rep. 25:1495-1502(2011).
//
RX   PubMed=21863025; DOI=10.1038/bjc.2011.324; PMCID=PMC3185940;
RA   De Luca A., Lamura L., Strizzi L., Roma C., D'Antonio A.,
RA   Margaryan N.V., Pirozzi G., Hsu M.-Y., Botti G., Mari E., Hendrix M.J.C.,
RA   Salomon D.S., Normanno N.;
RT   "Expression and functional role of CRIPTO-1 in cutaneous melanoma.";
RL   Br. J. Cancer 105:1030-1038(2011).
//
RX   PubMed=29492214; DOI=10.18632/oncotarget.23989; PMCID=PMC5823576;
RA   Sini M.C., Doneddu V., Paliogiannis P., Casula M., Colombino M.,
RA   Manca A., Botti G., Ascierto P.A., Lissia A., Cossu A., Palmieri G.;
RT   "Genetic alterations in main candidate genes during melanoma
RT   progression.";
RL   Oncotarget 9:8531-8541(2018).
//